1. Generics Bulletin

Biogen’s Tecfidera Resilience Reflects ‘Inefficiencies In US System’

Payment Quirk Also Means Doctors Currently ‘May Prefer Vumerity’

 
• By Dean Rudge

Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.

climbing mountain
Tecfidera sales showed resilience in Q3 • Source: Alamy

The “success” of Biogen’s Tecfidera (dimethyl fumarate) in the US in the third quarter of 2021, in the face of a plethora of generic versions of the former blockbuster treatment for multiple sclerosis, reflects a “broader problem,” and represents a “combination of several inefficiencies in the US system,” according to a leading US brokerage.

After a West Virginia district court in June last year invalidated Biogen’s US patent 8,399,514, which was due to protect...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

‘I Saw An Unpolished Diamond’: Iconovo CEO Wäborg On Breaking Even In 2027 And Beyond

 
• By Dean Rudge

In an exclusive interview, Iconovo CEO Johan Wäborg outlines the company’s strategy to become a leader in dry powder inhalation by focusing on platform development, reformulated therapies, and B2B licensing, with a plan to break even by 2027.

Lupin Looks To Expand In China With Respiratory Alliance

 
• By Dave Wallace

Lupin is planning to expand its footprint in China through a deal for a tiotropium dry powder inhaler with local player Sino Universal Pharmaceuticals.

Welch Heads Up Par Ahead Of Planned Spin-Off After Endo-Mallinckrodt Merger

 
• By Dave Wallace

As Endo and Mallinckrodt continue to work towards consummating the merger they announced earlier this year, the pair have revealed further organizational details of their combined generics and sterile injectables business, which is set to be spun off after the merger is complete.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

More from Products